Clinical trials: Peritoneal Malignancy
Gastric Cancer Stage IV, Peritoneal Carcinomatosis
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
- Trial name
- IPLUS (NCT03618758)
- Testing
- Paclitaxel, mFOLFOX6 regimen
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Seoul National University Bundang Hospital
Ovarian Cancer, Fallopian Tube Cancer
Study of Ramucirumab in Ovarian Cancer
The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT00721162
- Testing
- Ramucirumab
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Cancer, Fallopian Tube Cancers
A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate approved for the treatment of ovarian cancer. However, real-world data on its safety and effectiveness in routine clinical practice are limited, especially in the…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- MIRAS (NCT07690332)
- Testing
- Mirvetuximab Soravtansine (MIRV)
- Volunteers
- 400 people
- Sponsor
- NING LI-GYN
Ovarian Cancer, Peritoneal Cancer
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer.
- Trial name
- NCT00055432
- Testing
- Gemzar and Alimta
- Where
- United States
- Sponsor
- Eli Lilly and Company
Colon Cancer, Rectal Cancer
Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy
The objective of this study is to investigate whether the use of Human Peritoneal Membrane (HPM) in a temporary loop ileostomy is beneficial to patients.
- Trial name
- AlloMem (NCT01113736)
- Testing
- AlloMEM™
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Fallopian Tube Cancer, Ovarian Cancer
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00006391
- Testing
- oxaliplatin, topotecan hydrochloride
- Where
- United States
- Sponsor
- NYU Langone Health
Mesothelioma
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Study chemotherapy will consist of four treatments with Velcade (days 1, 4, 15, and 18) and two treatments with Eloxatin(days 4 and 18).
- Trial name
- NCT00996385
- Testing
- Velcade (bortezomib) plus Eloxatin (oxaliplatin)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Columbia University
Peritoneal Metastasis, Gastric Cancer
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
- Trial name
- NCT06597526
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
Solid Tumor, Peritoneal Metastases
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
This is an open-label, non-randomized, multicenter, Phase 1/2a study to evaluate the safety and potential efficacy of Allocetra-OTS in the treatment of advanced solid tumor malignancy as monotherapy or in combination with an…
- Conditions
- Solid Tumor, Peritoneal Metastases, Peritoneal Cancer
- Trial name
- NCT05581719
- Testing
- Allocetra-OTS, Nivolumab, Tislelizumab
- Where
- 6 sites in Israel, Spain
- Volunteers
- 14 people
- Sponsor
- Enlivex Therapeutics RDO Ltd.
Ovarian, Fallopian Tube and Peritoneal Cancer
A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a phase-I, dose escalation study to assess the safety and biological activity of cyclophosphamide/fludarabine lymphodepletion followed by adoptive transfer of vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood…
- Trial name
- NCT02277392
- Testing
- Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells, SB---485232 (Human recombinant Interleukin---18)
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7
- Trial name
- NCT02042430
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
This phase II trial is studying how well giving sorafenib together with gemcitabine works in treating patients with recurrent or refractory ovarian cancer or primary peritoneal cancer.
- Trial name
- NCT00096395
- Testing
- gemcitabine hydrochloride, sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Ovarian Neoplasm, Ovarian Carcinoma
PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
This trial studies how well positron emission tomography/magnetic resonance (PET/MR) versus contrast enhanced computerized tomography (CECT) scans work in locating ovarian cancer tumors in patients with known or suspected ovarian…
- Trial name
- NCT03965481
- Testing
- Dynamic Enhanced CT, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Stomach Neoplasm
Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor
Gastric cancer with positive is defined as stage IV disease in 7th AJCC/UICC TNM staging system. Controversy exists on the treatment of this part of patients.
- Trial name
- Cy-plus (NCT02969122)
- Testing
- standard gastrectomy with D2 lymphadenectomy, hyperthermic intraperitoneal chemotherapy, Extensive intraperitoneal lavage
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Peking University
Peritoneum; Carcinomatosis, Peritoneal Neoplasms
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -
This is a study, where the efficacy of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) against peritoneal metastases will be evaluated.
- Conditions
- Peritoneum; Carcinomatosis, Peritoneal Neoplasms, Peritoneal Metastases, Chemotherapy Effect
- Trial name
- PIPAC-OPC2 (NCT03287375)
- Testing
- PIPAC
- Where
- Denmark
- Volunteers
- 143 people
- Sponsor
- Michael Bau Mortensen
Gastric Cancer
A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
Peritoneal metastasis is the main factor leading to poor prognosis in patients with gastric cancer or colorectal cancer. Although current systemic treatment regimens can prolong the time to peritoneal metastasis, the long-term…
- Trial name
- NCT06496919
- Testing
- Recombinant Mutant Human Tumor Necrosis Factor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Wuhan University
Ovarian Cancer
Fermented Wheat Germ Extract in Women With Ovarian Cancer
The main purpose of this Pilot Study is to test the safety, tolerability and quality of life in women who take Fermented Wheat Germ Extract (FWGE), to determine if an active form of FWGE can be detected in the blood, and…
- Trial name
- NCT02411565
- Testing
- Fermented Wheat Germ Extract (FWGE), Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.